Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure

Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure

Source: 
Xconomy
snippet: 

An experimental treatment for Duchenne muscular dystrophy has failed a mid-stage study, and Summit Therapeutics said Wednesday it is now stopping work on the drug. Summit shares plunged nearly 80 percent on the news.